NASDAQ
MNPR

Monopar Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Monopar Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.5668
Today's High:
$0.6199
Open Price:
$0.6
52W Low:
$0.5668
52W High:
$4.88
Prev. Close:
$0.585
Volume:
39603

Company Statistics

Market Cap.:
$9.02 million
Book Value:
0.564
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-46.95%
Return on Equity TTM:
-88.85%

Company Profile

Monopar Therapeutics Inc had its IPO on 2019-12-19 under the ticker symbol MNPR.

The company operates in the Healthcare sector and Biotechnology industry. Monopar Therapeutics Inc has a staff strength of 11 employees.

Stock update

Shares of Monopar Therapeutics Inc opened at $0.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.57 - $0.62, and closed at $0.59.

This is a +0.02% increase from the previous day's closing price.

A total volume of 39,603 shares were traded at the close of the day’s session.

In the last one week, shares of Monopar Therapeutics Inc have slipped by -8.15%.

Monopar Therapeutics Inc's Key Ratios

Monopar Therapeutics Inc has a market cap of $9.02 million, indicating a price to book ratio of 2.7233 and a price to sales ratio of 0.

In the last 12-months Monopar Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Monopar Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Monopar Therapeutics Inc’s operating margin was 0% while its return on assets stood at -46.95% with a return of equity of -88.85%.

In Q2, Monopar Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Monopar Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Monopar Therapeutics Inc’s profitability.

Monopar Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.9179. Its price to sales ratio in the trailing 12-months stood at 0.

Monopar Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.34 million
Total Liabilities
$2.50 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Monopar Therapeutics Inc ended 2024 with $10.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.34 million while shareholder equity stood at $7.84 million.

Monopar Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.50 million in other current liabilities, 13898.00 in common stock, $-56438568.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.21 million and cash and short-term investments were $10.19 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Monopar Therapeutics Inc’s total current assets stands at $10.30 million while long-term investments were $0 and short-term investments were $2.98 million. Its net receivables were $0 compared to accounts payable of $2.50 million and inventory worth $0.

In 2024, Monopar Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Monopar Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.59
52-Week High
$4.88
52-Week Low
$0.5668
Analyst Target Price
$8.5

Monopar Therapeutics Inc stock is currently trading at $0.59 per share. It touched a 52-week high of $4.88 and a 52-week low of $4.88. Analysts tracking the stock have a 12-month average target price of $8.5.

Its 50-day moving average was $0.72 and 200-day moving average was $1.74 The short ratio stood at 0.63 indicating a short percent outstanding of 0%.

Around 6800.3% of the company’s stock are held by insiders while 167.1% are held by institutions.

Frequently Asked Questions About Monopar Therapeutics Inc

The stock symbol (also called stock or share ticker) of Monopar Therapeutics Inc is MNPR

The IPO of Monopar Therapeutics Inc took place on 2019-12-19

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$10.68
-0.2
-1.84%
Ametek Inc (AME)
$151.66
-1.79
-1.17%
Exponent Inc (EXPO)
$89.32
0.72
+0.81%
$2349.7
-1.95
-0.08%
Premier Limited (PREMIER)
$2.3
0.1
+4.55%
$1.36
0
0%
$2682.85
-220.1
-7.58%
$3.39
-0.04
-1.02%
$5.65
0.06
+1.07%
$0.04
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Address

1000 Skokie Boulevard, Wilmette, IL, United States, 60091